• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and...

cafead

Administrator
Staff member
  • cafead   Sep 19, 2020 at 09:42: PM
via Sometimes in oncology, where both the unmet need and the level of competition are high, when you see a signal, you go for it. Taking on a bit more risk to head into phase 3 can make sense "because the patients are waiting and the business opportunity is in front of you,” as one Pfizer exec put it.

article source
 

<